UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice TargetHot
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.